Moreover, differentiated thyroid cancer patients who received therapeutic higher doses of thyroid hormone replacement, resulting in factitious subclinical hyperthyroidism, showed an increase risk of osteoporosis [13–14]. This evidence concerns the gene TG and hyperthyroidism.